Literature DB >> 1154312

Further investigations on antithrombin III in the plasmas of patients with the abnormality of antithrombin III Budapest.

G Sas, D S Pepper, J D Cash.   

Abstract

Antithrombin III (AT-III) was studied in a thrombophilic family with an abnormal AT-III molecule (antithrombin III Budapest) using a modified crossed immunoelectrophoresis technique, gel filtration, 'rocket' immunoelectrophoresis and a heparin cofactor assay. When agarose was applied in the first phase of the crossed immunoelectrophoresis, the normal and the pathological AT-III revealed identical electrophoretic mobility. However, when heparin was mixed with agarose in the first phase of electrophoresis, the propositus' plasma displayed a different AT-III pattern from normal plasma. His plasma contained the first component of the normal plasma (Immune Antithrombin III1, IAT-III) in a concentration of only 5% of normal, and a protein in high concentration which although immunoreactive to AT-III antisera, had an electrophoretic mobility similar (but not identical to that of IAT-III2. This abnormal protein had no heparin cofactor activity and a molecular size greater than normal plasma AT-III. Unlike AT-III, the addition of heparin did not change the molecular size of the pathogic AT-III molecule significantly. The abnormal protein was present in lower concentrations in the patient's children and at the time of study they had no clinical or laboratory evidence of intravascular coagulation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1154312

Source DB:  PubMed          Journal:  Thromb Diath Haemorrh        ISSN: 0340-5338


  5 in total

1.  In vitro and in vivo correlation of clotting protease activity: effect of heparin.

Authors:  S N Gitel; R C Stephenson; S Wessler
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

2.  Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").

Authors:  J E Sambrano; L J Jacobson; E B Reeve; M J Manco-Johnson; W E Hathaway
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

Review 3.  Familial venous thrombosis.

Authors:  J H Winter; A S Douglas
Journal:  Postgrad Med J       Date:  1983-11       Impact factor: 2.401

4.  Antithrombin III (AT III) Padua2: a "new" congenital abnormality with defective heparin co-factor activities but no thrombotic disease.

Authors:  A Girolami; F Fabris; G Cappellato; L Sainati; G Boeri
Journal:  Blut       Date:  1983-08

5.  Depressed antithrombin III biological activity in opiate addicts.

Authors:  A Ceriello; P Dello Russo; F Curcio; A Tirelli; D Giugliano
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.